Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection.

Vineet D Menachery1,2 Kenneth H Dinnon2,3 Boyd L Yount2 Eileen T McAnarney1,2 Lisa E Gralinski2 Andrew Hale3 Rachel L Graham2 Trevor Scobey2 Simon J Anthony4,5 Lingshu Wang6 Barney Graham6 Scott H Randell7 W Ian Lipkin4,5 Ralph S Baric8,3
Affiliations 8 institutions
  1. Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
  2. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  3. Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
  4. Center for Infection and Immunity, Mailman School of Public Health, Columbia University, New York, New York, USA.
  5. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York.
  6. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
  7. Department of Cell Biology and Physiology, and Marsico Lung Institute/Cystic Fibrosis Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  8. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA [email protected].

Abstract

Traditionally, the emergence of coronaviruses (CoVs) has been attributed to a gain in receptor binding in a new host. Our previous work with severe acute respiratory syndrome (SARS)-like viruses argued that bats already harbor CoVs with the ability to infect humans without adaptation. These results suggested that additional barriers limit the emergence of zoonotic CoV. In this work, we describe overcoming host restriction of two Middle East respiratory syndrome (MERS)-like bat CoVs using exogenous protease treatment. We found that the spike protein of PDF2180-CoV, a MERS-like virus found in a Ugandan bat, could mediate infection of Vero and human cells in the presence of exogenous trypsin. We subsequently show that the bat virus spike can mediate the infection of human gut cells but is unable to infect human lung cells. Using receptor-blocking antibodies, we show that infection with the PDF2180 spike does not require MERS-CoV receptor DPP4 and antibodies developed against the MERS spike receptor-binding domain and S2 portion are ineffective in neutralizing the PDF2180 chimera. Finally, we found that the addition of exogenous trypsin also rescues HKU5-CoV, a second bat group 2c CoV. Together, these results indicate that proteolytic cleavage of the spike, not receptor binding, is the primary infection barrier for these two group 2c CoVs. Coupled with receptor binding, proteolytic activation offers a new parameter to evaluate the emergence potential of bat CoVs and offers a means to recover previously unrecoverable zoonotic CoV strains.IMPORTANCE Overall, our studies demonstrate that proteolytic cleavage is the primary barrier to infection for a subset of zoonotic coronaviruses. Moving forward, the results argue that both receptor binding and proteolytic cleavage of the spike are critical factors that must be considered for evaluating the emergence potential and risk posed by zoonotic coronaviruses. In addition, the findings also offer a novel means to recover previously uncultivable zoonotic coronavirus strains and argue that other tissues, including the digestive tract, could be a site for future coronavirus emergence events in humans.

coronavirus 195 emergence 10 MERS-CoV 24 PDF2180 0 spike 25 zoonotic 23 Animals 1948 Caco-2 Cells 3 Chiroptera 371 Chlorocebus aethiops 70 Coronavirus Infections 171 Humans 1440 Middle East Respiratory Syndrome Coronavirus 68 Receptors, Virus 204 Spike Glycoprotein, Coronavirus 274 Trypsin 5 Vero Cells 55 Zoonoses 397

Evidence records

0 total

No structured evidence records are linked to this article.